Johns Hopkins University

Researchers

• DLDung T Le

Running trials

• Not yet recruiting

  Addressing Health Disparities in Normal Pressure Hydrocephalus (NPH) in Maryland

  NCT06426004· Johns Hopkins Bloomberg School of Public Health· Source

• Not yet recruiting

  Safety Study of XT-150 in Participants With ALS

  NCT06704347· Phase 1· Xalud Therapeutics, Inc.· Source

• Not yet recruiting

  Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies

  NCT07240805· BioSensics· Source

• Not yet recruiting

  Oral N-acetylglucosamine in Crohn's Disease

  NCT07225998· Phase 2· Johns Hopkins University· Source

• Not yet recruiting

  Testing Heart Failure Resilience Intervention for Caregivers (HEROIC) in Advanced Heart Failure

  NCT07805811· Phase 2· Johns Hopkins University· Source

• Not yet recruiting

  Brain Imaging of DSP-2342

  NCT07850102· Phase 2· Johns Hopkins University· Source

• Recruiting

  Linking Youth to Pre-Exposure Prophylaxis (PrEP) Services

  NCT07438041· Westat· Source

• Recruiting

  Can Mindfulness and Virtual Reality Reduce Stress in Young Adults With Type 1 Diabetes?

  NCT07793097· Wayne State University· Source

• Not yet recruiting

  ED Patient's Perceptions and Acceptability Toward a Novel POC HCV Viral Load Testing

  NCT03767231· Johns Hopkins University· Source

• Recruiting

  Liver Transplantation From Donors With HIV: Impact on Opportunistic Infections, Cancer, and Long-Term Outcomes (Expanding HOPE Liver)

  NCT07665372· Johns Hopkins University· Source

• Not yet recruiting

  A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotemporal Dementia Spectrum

  NCT07569367· BioSensics· Source

• Recruiting

  Peer Support for Liver Transplant Recipients With History of ALD

  NCT07397598· Johns Hopkins University· Source

• Recruiting

  Expanding HOPE Liver

  NCT07778459· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Recruiting

  WATER IV PCa (AS Sub-study)

  NCT07650448· PROCEPT BioRobotics· Source

• Recruiting

  PSMA-High: EBRT/ PSMA617/ ADT vs. EBRT/ ADT

  NCT07550517· Phase 2· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Recruiting

  An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

  NCT06996652· Phase 2· Yale University· Source

• Enrolling by invitation

  Stimulant and Polysubstance Use, Inflammation, and Sex Effects on Myocardial Disease in HIV

  NCT07461350· University of California, San Francisco· Source

• Recruiting

  PRE-EMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis

  NCT07232069· Phase 3· Duke University· Source

• Recruiting

  Pridopidine Phase 3 Study in Huntington's Disease

  NCT07609108· Phase 3· Prilenia· Source

• Recruiting

  Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV

  NCT07040319· Phase 1/2· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Recruiting

  Screen2Prevent (S2P)

  NCT07728123· Westat· Source

• Recruiting

  A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer

  NCT07644559· Phase 2· Verastem, Inc.· Source

• Recruiting

  Implementation of a Beauty Salon-Based Strategy for Blood Pressure Management Among Women

  NCT07042386· Johns Hopkins University· Source

• Recruiting

  Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

  NCT07621718· Phase 3· Revolution Medicines, Inc.· Source

• Active, not recruiting

  An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

  NCT07517263· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma

  NCT07226453· Phase 2· University of California, San Francisco· Source

• Recruiting

  Precision Radiotherapy Enabled by Molecular MRI

  NCT07512154· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Recruiting

  Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis

  NCT07497399· Phase 2· Johns Hopkins University· Source

• Recruiting

  A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

  NCT07143968· Phase 2· Naga P. Chalasani· Source

• Recruiting

  A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

  NCT07419295· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)

  NCT07486960· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

  NCT07287670· Phase 2· Mediar Therapeutics· Source

• Recruiting

  Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

  NCT07297979· Phase 1· Amgen· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

  NCT07351045· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Trial of Food Is Medicine Approaches for Obesity Treatment in Adults With Food Insecurity

  NCT07396805· Johns Hopkins University· Source

• Recruiting

  Anastomotic Safety and Surveillance Using Real-time Enhanced Sensing Using xBar

  NCT07337590· Exero Medical Ltd.· Source

• Recruiting

  Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

  NCT07059091· Phase 2· Johns Hopkins University· Source

• Recruiting

  Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

  NCT07389590· Phase 4· Johns Hopkins University· Source

• Recruiting

  CF Wellness Program

  NCT07071324· Johns Hopkins University· Source

• Recruiting

  Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)

  NCT07247058· Phase 4· Johns Hopkins University· Source

• Recruiting

  Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

  NCT07322003· Phase 3· Prilenia· Source

• Recruiting

  Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1

  NCT07102394· Phase 1· Johns Hopkins University· Source

• Recruiting

  Addressing Hypertension Care in Africa Program

  NCT06986590· Johns Hopkins University· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder

  NCT07227454· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers

  NCT07349758· Phase 1· Johns Hopkins University· Source

• Active, not recruiting

  C-Raven, a Virtual Tobacco Cessation Intervention in Residency Clinics

  NCT07220356· Phase 4· Johns Hopkins University· Source

• Recruiting

  Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

  NCT07195591· Phase 3· GT Medical Technologies, Inc.· Source

• Recruiting

  Acquired Dyslexia Modeling and Treatment

  NCT07209488· Rutgers, The State University of New Jersey· Source

• Active, not recruiting

  A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

  NCT07074886· Phase 2· Hoffmann-La Roche· Source

Showing 50 of 267.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers12 recruiting
• HIV11 recruiting
• Lung cancer9 recruiting
• Prostate cancer9 recruiting
• Heart failure7 recruiting
• Pancreatic cancer7 recruiting
• Cystic fibrosis6 recruiting
• High blood pressure5 recruiting
• Obesity5 recruiting
• Alzheimer disease4 recruiting
• Bladder cancer4 recruiting
• Colorectal cancer4 recruiting
• Hepatitis C4 recruiting
• Sarcoma4 recruiting
• Stroke4 recruiting
• Type 1 diabetes4 recruiting
• Type 2 diabetes4 recruiting
• ALS (motor neurone disease)3 recruiting
• Coronary artery disease3 recruiting
• Crohn's disease3 recruiting
• Frontotemporal dementia3 recruiting
• Head and neck cancer3 recruiting
• Huntington's disease3 recruiting
• Insomnia3 recruiting
• Macular degeneration3 recruiting
• Multiple sclerosis3 recruiting
• Acute lymphoblastic leukaemia2 recruiting
• Acute myeloid leukaemia2 recruiting
• Amyloidosis2 recruiting
• Antiphospholipid syndrome2 recruiting
• Aplastic anaemia2 recruiting
• Charcot-Marie-Tooth disease2 recruiting
• Chronic kidney disease2 recruiting
• COPD2 recruiting
• Endometrial cancer2 recruiting
• Epilepsy2 recruiting
• Glioblastoma2 recruiting
• Melanoma2 recruiting
• Neurofibromatosis type 12 recruiting
• Ovarian cancer2 recruiting
• Parkinson disease2 recruiting
• Pulmonary arterial hypertension2 recruiting
• Sickle cell disease2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Alopecia areata1 recruiting
• Aortic stenosis1 recruiting
• Asthma1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Atrial fibrillation1 recruiting
• Brain aneurysm1 recruiting
• Cervical cancer1 recruiting
• Congenital heart disease1 recruiting
• Cushing's syndrome1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Depression1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Hearing loss1 recruiting
• Hodgkin lymphoma1 recruiting
• Hydrocephalus1 recruiting
• Immune thrombocytopenia (ITP)1 recruiting
• Kidney cancer1 recruiting
• Lewy body dementia1 recruiting
• Liver and biliary tract cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Mild cognitive impairment1 recruiting
• Mitochondrial disease1 recruiting
• Multiple myeloma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Myocarditis1 recruiting
• Optic neuritis1 recruiting
• Osteonecrosis (avascular necrosis)1 recruiting
• Rheumatoid arthritis1 recruiting
• Sarcoidosis1 recruiting
• Schizophrenia1 recruiting
• Spinal cord injury1 recruiting
• Tourette syndrome1 recruiting
• Ulcerative colitis1 recruiting
• Vascular dementia1 recruiting

Closed trials

• Withdrawn

  Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder

  NCT06005662· Phase 2· Johns Hopkins University· Source

• Completed

  OnTrackCF: Engagement, Feasibility, and Acceptability Study

  NCT07031323· Boston Children's Hospital· Source

• Withdrawn

  Developing and Pilot Testing a Remote Smoking Cessation Digital Therapeutic for Individuals With Serious Mental Illness

  NCT05031416· Johns Hopkins University· Source

• Terminated

  Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy

  NCT06543446· University of Rochester· Source

• Completed

  A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

  NCT06637423· Phase 1/2· Merck Sharp & Dohme LLC· Source

• Completed

  C-Raven, a Virtual Tobacco Cessation Intervention in the Community

  NCT06545669· Phase 4· Johns Hopkins University· Source

• Terminated

  ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

  NCT06418711· Phase 3· Mannkind Corporation· Source

• Completed

  A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

  NCT06159725· Phase 1/2· Clarametyx Biosciences, Inc.· Source

• Completed

  AdapTive Personalized Dietitian coacHing, Messaging and pRoduce prescrIption to improVE Healthy Dietary Behaviors

  NCT06257550· Johns Hopkins University· Source

• Terminated

  Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging)

  NCT06445127· Johns Hopkins University· Source

• Completed

  Testing C-Raven, a Virtual Tobacco Cessation Intervention, in the Community

  NCT06289192· Phase 4· Johns Hopkins University· Source

• Completed

  Assessing Effectiveness of a Diabetes Navigator in Increasing Progression of Advanced Diabetes Technologies

  NCT06229236· Johns Hopkins University· Source

• Completed

  Adaptation and Feasibility of the Community-Based Anxiety Program Tailored for Autism (CAPTA)

  NCT06046170· Baylor College of Medicine· Source

• Completed

  Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease

  NCT05861453· Phase 2· Afimmune· Source

• Terminated

  Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

  NCT06077773· Phase 2· Escient Pharmaceuticals, Inc· Source

• Terminated

  Home-based tDCS in Frontotemporal Dementia or Alzheimer's Disease

  NCT05978804· Johns Hopkins University· Source

• Completed

  Analysis of Cellular Kinases and Aging in PBMCs and Colorectal Tissue

  NCT06132386· Johns Hopkins University· Source

• Completed

  Health Outcomes of Parents With Cystic Fibrosis

  NCT05829694· University of Pittsburgh· Source

• Completed

  Patient Centered Mobile Health Technology Enabled Atrial Fibrillation Management

  NCT05400837· Johns Hopkins University· Source

• Terminated

  Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS

  NCT05918978· Phase 2· argenx· Source

• Recruiting

  A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  NCT05442567· Phase 3· Takeda· Source

• Terminated

  Altropane Dose for Imaging Patients With Suspected Parkinson's Disease

  NCT05636852· Phase 2· GE Healthcare· Source

• Withdrawn

  D-cycloserine Augmented Treatment for Youth With Tic Disorders

  NCT04357951· Early phase 1· Johns Hopkins University· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Impact of a Corrie Cardiac Rehabilitation Program

  NCT05238103· Johns Hopkins University· Source

• Completed

  Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

  NCT05819359· Phase 2· Bial R&D Investments, S.A.· Source

• Completed

  An Observational Biomarker Study in Multiple Sclerosis (MS) Patients

  NCT05663853· LAPIX Therapeutics Inc.· Source

• Completed

  Community Active and Healthy Families

  NCT04414553· University of Colorado, Denver· Source

• Completed

  Quantifying Myofascial Dysfunction in Post-Stroke Pain

  NCT05762679· Johns Hopkins University· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

  NCT05721573· Phase 2/3· Abcuro, Inc.· Source

• Withdrawn

  Wald Outreach for Wellness: Blood Pressure Outreach

  NCT04286568· Johns Hopkins University· Source

• Terminated

  Study of M5049 in DM and PM Participants (NEPTUNIA)

  NCT05650567· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

  NCT05616221· Phase 2· Armata Pharmaceuticals, Inc.· Source

• Completed

  Optimizing Cerebral Autoregulation During Surgery

  NCT05308290· Johns Hopkins University· Source

• Terminated

  RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis

  NCT05298358· Phase 1· Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins· Source

• Completed

  Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF

  NCT05284617· Phase 2· Rivus Pharmaceuticals, Inc.· Source

• Completed

  A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

  NCT05453578· Phase 1/2· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• Completed

  Efficacy and Safety Study of Efgartigimod in Adults With Post-COVID-19 POTS

  NCT05633407· Phase 2· argenx· Source

• Completed

  Breast and Cervical Cancer Education Program

  NCT06365450· Johns Hopkins University· Source

• Completed

  EPPIC-Net: Platform Protocol to Assess Treatments for Painful Diabetic Peripheral Neuropathy

  NCT05476276· Phase 2· James P. Rathmell, MD· Source

• Completed

  EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA

  NCT05480228· Phase 2· James P. Rathmell, MD· Source

• Completed

  Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors

  NCT05383872· InSightec· Source

• Completed

  Family Diabetes Prevention Program Pilot Study

  NCT05358444· Johns Hopkins University· Source

• Completed

  A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies

  NCT05379634· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot Ulcers

  NCT05579743· Johns Hopkins University· Source

• Completed

  Study of ATH434 in Participants with Multiple System Atrophy

  NCT05109091· Phase 2· Alterity Therapeutics· Source

• Completed

  Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma

  NCT05421598· Phase 2· Sanofi· Source

• Completed

  A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease

  NCT05218655· Phase 3· PTC Therapeutics· Source

• Completed

  A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers

  NCT05360680· Phase 1· Cue Biopharma· Source

• Completed

  Investigating Distress Tolerance in Adults With Tourette Syndrome

  NCT05047705· Johns Hopkins University· Source

Showing 50 of 146.

Conditions

Diseases this institution publishes on or runs trials for.

• HIV789 works · 21 trials
• Stroke560 works · 12 trials
• Obesity433 works · 18 trials
• Alzheimer disease405 works · 13 trials
• Heart failure361 works · 11 trials
• Tuberculosis249 works · 1 trial
• Prostate cancer230 works · 22 trials
• Lung cancer219 works · 18 trials
• Type 2 diabetes214 works · 8 trials
• Chronic kidney disease187 works · 3 trials
• Atrial fibrillation150 works · 6 trials
• Asthma147 works · 3 trials
• Pancreatic cancer141 works · 9 trials
• Multiple sclerosis140 works · 13 trials
• Epilepsy139 works · 7 trials
• Melanoma133 works · 2 trials
• Deep vein thrombosis and pulmonary embolism128 works · 2 trials
• Liver and biliary tract cancer125 works · 3 trials
• Schizophrenia120 works · 1 trial
• Colorectal cancer116 works · 7 trials
• Mild cognitive impairment108 works · 5 trials
• Parkinson disease105 works · 5 trials
• Glioblastoma100 works · 7 trials
• Bladder cancer99 works · 12 trials
• Cystic fibrosis96 works · 14 trials
• Hearing loss96 works · 1 trial
• COPD95 works · 6 trials
• Sarcoma88 works · 11 trials
• Coronary artery disease75 works · 11 trials
• Kidney cancer73 works · 5 trials